|
|
(1) Inhaled products of the modern era: drugs for non-respiratory conditions
In this first article in a series that will look at developments
in new drug technologies, Jenny Bryan describes the development
of products for pulmonary delivery including formulations of
insulin, analgesics and drugs for erectile dysfunction
(PDF
45K)
Pharmaceutical Journal, 2004; 273; 161-162 (31 July 2004)
|
|
(2) Transdermal drug delivery may be a common technique in the future
In this second article in our series looking at developments in new drug technologies,
Jenny Bryan describes the techniques that companies throughout the world are
developing to push drugs through the skin
(PDF 45K)
Pharmaceutical Journal, 2004; 273; 292-293 (28 August 2004)
|
|
(3) Crossing the blood-brain barrier: drug delivery to the brain is still elusive
In this third article in our series looking at developments in drug technologies,
Jenny Bryan describes the development of techniques to get drugs across the
blood-brain barrier
(PDF 45K)
Pharmaceutical Journal, 2004; 273; 475-476 (2 October 2004)
|
|
(4) Getting systemic treatments into the bloodstream via the nasal mucosa
In this fourth article in our series looking developments in drug technologies, Jenny Bryan describes development of techniques for getting drugs into the body, and even the brain, via nasal inhalation
(PDF 45K)
Pharmaceutical Journal, 2004; 273; 649-650 (30 October 2004)
|
|
(5) What role will dendrimer-based drug technology have in the future?
In the fifth article in our series looking developments in drug technologies,
Jenny Bryan describes how dendrimer nanoparticles are being used to prevent
the transmission of HIV and to improve the bioavailability of some drugs
(PDF 150K)
Pharmaceutical Journal, 2004; 273; 793-794 (27 November 2004)
|
|
(6) Development of drug delivery systems that match the circadian rhythm
In the sixth article in our series looking at developments in drug technologies, Jenny Bryan describes why emphasis should now be placed on the development of drug delivery systems that take account of variations in bodily functions, such as blood pressure, during the day and night
(PDF 240K)
(PDF 40K
— no graphics)
Pharmaceutical Journal, 2005; 274; 90-91 (22 January 2005)
|
|
(7) Novel inhaler devices: balancing innovation against price is important
In the seventh article in our series looking at developments in drug technologies,
Jenny Bryan describes the development of novel inhaler devices for delivery
of drugs for asthma and chronic obstructive pulmonary disease
(PDF 130K)
Pharmaceutical Journal, 2005; 274; 241-242 (26 February 2005)
|
|
(8) How new drug technologies might overcome toxicity from chemotherapy
A new approach to cytotoxic drug delivery, which addresses problems of tumour
resistance and drug toxicity, is the subject of the latest article in our new
drug technologies series. Jenny Bryan reports
(PDF 60K)
Pharmaceutical Journal, 2005; 274; 397 (2 April 2005)
|
| (9) Novel therapies: prostate cancer
In the ninth article in our series looking at developments in drug technologies,
Jenny Bryan describes new drugs on the horizon for patients with advanced
prostate cancer
(PDF 170K)
Pharmaceutical Journal, 2005; 274; 555-556 (7 May 2005)
|
| (10) Microdoses open new horizons for trials
In the 10th article in our series looking at developments in drug technologies,
Jenny Bryan looks at a new clinical trial technique with huge potential
(PDF 50K)
Pharmaceutical Journal, 2005; 275; 54 (9 July 2005)
|
|
|
